Polycystic Kidney Disease (Genitourinary Disorders) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Polycystic Kidney Disease – Drugs In Development, 2021, provides an overview of the Polycystic Kidney Disease (Genetic Disorders) pipeline landscape.

Polycystic kidney disease (PKD) is a disorder in which clusters of cysts develop primarily within kidneys. Polycystic kidney disease symptoms may include high blood pressure, back or side pain, headache, blood in urine, frequent urination and kidney failure. The predisposing factors include age and family history. Treatment includes antihypertensive drugs and diuretics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Polycystic Kidney Disease – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Polycystic Kidney Disease (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Polycystic Kidney Disease (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Polycystic Kidney Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 4, 3, 16 and 13 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 2 molecules, respectively.

Polycystic Kidney Disease (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Polycystic Kidney Disease (Genetic Disorders).

– The pipeline guide reviews pipeline therapeutics for Polycystic Kidney Disease (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Polycystic Kidney Disease (Genetic Disorders) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Polycystic Kidney Disease (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Polycystic Kidney Disease (Genetic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Polycystic Kidney Disease (Genetic Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Polycystic Kidney Disease (Genetic Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

AceLink Therapeutics Inc

Amathus Therapeutics Inc

AmMax Bio Inc

Angion Biomedica Corp

ATLAS Molecular Pharma SL

Bristol Myers Squibb Co

Camurus AB

Centessa Pharmaceuticals Plc

Chinook Therapeutics Inc

DiscoveryBiomed Inc

Eloxx Pharmaceuticals Inc

Galapagos NV

Generian Pharmaceuticals Inc

GLG Pharma SA

Goldfinch Bio Inc

Healx Ltd

IC-MedTech Inc

Ipsen SA

Kadmon Corp LLC

ManRos Therapeutics

Mironid Ltd

Mitotherapeutix LLC

NovaTarg Therapeutics Inc

Otsuka Pharmaceutical Co Ltd

Poxel SA

Reata Pharmaceuticals Inc

Regulus Therapeutics Inc

Shanghai Alebund Pharmaceuticals Ltd

Surrozen Inc

XORTX Therapeutics Inc

Table of Contents

Table of Contents

Introduction

Polycystic Kidney Disease - Overview

Polycystic Kidney Disease - Therapeutics Development

Polycystic Kidney Disease - Therapeutics Assessment

Polycystic Kidney Disease - Companies Involved in Therapeutics Development

Polycystic Kidney Disease - Drug Profiles

Polycystic Kidney Disease - Dormant Projects

Polycystic Kidney Disease - Discontinued Products

Polycystic Kidney Disease - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Polycystic Kidney Disease, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Companies, 2021 (Contd..1)

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Products under Development by Companies, 2021 (Contd..2)

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Target, 2021 (Contd..1)

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Mechanism of Action, 2021 (Contd..1)

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Polycystic Kidney Disease – Pipeline by AceLink Therapeutics Inc, 2021

Polycystic Kidney Disease – Pipeline by Amathus Therapeutics Inc, 2021

Polycystic Kidney Disease – Pipeline by AmMax Bio Inc, 2021

Polycystic Kidney Disease – Pipeline by Angion Biomedica Corp, 2021

Polycystic Kidney Disease – Pipeline by ATLAS Molecular Pharma SL, 2021

Polycystic Kidney Disease – Pipeline by Bristol Myers Squibb Co, 2021

Polycystic Kidney Disease – Pipeline by Camurus AB, 2021

Polycystic Kidney Disease – Pipeline by Centessa Pharmaceuticals Plc, 2021

Polycystic Kidney Disease – Pipeline by Chinook Therapeutics Inc, 2021

Polycystic Kidney Disease – Pipeline by DiscoveryBiomed Inc, 2021

Polycystic Kidney Disease – Pipeline by Eloxx Pharmaceuticals Inc, 2021

Polycystic Kidney Disease – Pipeline by Galapagos NV, 2021

Polycystic Kidney Disease – Pipeline by Generian Pharmaceuticals Inc, 2021

Polycystic Kidney Disease – Pipeline by GLG Pharma SA, 2021

Polycystic Kidney Disease – Pipeline by Goldfinch Bio Inc, 2021

Polycystic Kidney Disease – Pipeline by Healx Ltd, 2021

Polycystic Kidney Disease – Pipeline by IC-MedTech Inc, 2021

Polycystic Kidney Disease – Pipeline by Ipsen SA, 2021

Polycystic Kidney Disease – Pipeline by Kadmon Corp LLC, 2021

Polycystic Kidney Disease – Pipeline by ManRos Therapeutics, 2021

Polycystic Kidney Disease – Pipeline by Mironid Ltd, 2021

Polycystic Kidney Disease – Pipeline by Mitotherapeutix LLC, 2021

Polycystic Kidney Disease – Pipeline by NovaTarg Therapeutics Inc, 2021

Polycystic Kidney Disease – Pipeline by Otsuka Pharmaceutical Co Ltd, 2021

Polycystic Kidney Disease – Pipeline by Poxel SA, 2021

Polycystic Kidney Disease – Pipeline by Reata Pharmaceuticals Inc, 2021

Polycystic Kidney Disease – Pipeline by Regulus Therapeutics Inc, 2021

Polycystic Kidney Disease – Pipeline by Shanghai Alebund Pharmaceuticals Ltd, 2021

Polycystic Kidney Disease – Pipeline by Surrozen Inc, 2021

Polycystic Kidney Disease – Pipeline by XORTX Therapeutics Inc, 2021

Polycystic Kidney Disease – Dormant Projects, 2021

Polycystic Kidney Disease – Dormant Projects, 2021 (Contd..1)

Polycystic Kidney Disease – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Polycystic Kidney Disease, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports